| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/07/2011 | US20110081370 Methods and Compositions for Modulating Immune Tolerance |
| 04/07/2011 | US20110081366 Immunostimulatory nucleic acid molecules |
| 04/07/2011 | US20110081364 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| 04/07/2011 | US20110081362 Treatment of cancer |
| 04/07/2011 | US20110081361 Antibodies that bind interleukin-4 receptor |
| 04/07/2011 | US20110081359 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 04/07/2011 | US20110081356 Anti-cancer drug |
| 04/07/2011 | US20110081355 Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies |
| 04/07/2011 | US20110081354 Anti-ctla-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| 04/07/2011 | US20110081353 Antibody against the csf-1 r |
| 04/07/2011 | US20110081352 Immunogenic peptides and methods of use for treating and preventing cancer |
| 04/07/2011 | US20110081350 Synthetic scFv Analogue To The 6313/G2 (Anti Angiotensin II Type 1 Receptor) Monoclonal Antibody Variable Regions |
| 04/07/2011 | US20110081347 Antibodies with Altered Binding to FcRn and Methods of Using Same |
| 04/07/2011 | US20110081346 B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
| 04/07/2011 | US20110081345 Single chain fc, methods of making and methods of treatment |
| 04/07/2011 | US20110081343 Vaccines directed to langerhans cells |
| 04/07/2011 | US20110081342 Anti-vegf antibodies |
| 04/07/2011 | US20110081341 Immunopotentiative composition |
| 04/07/2011 | US20110081338 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
| 04/07/2011 | US20110081337 Function of gpr4 in vascular inflammatory response to acidosis and related methods |
| 04/07/2011 | US20110081331 Cancer therapy |
| 04/07/2011 | US20110081323 Methods and compositions for organ and tissue functionality |
| 04/07/2011 | US20110081313 Mechanism of action of primary cell derived biologic |
| 04/07/2011 | US20110081293 Methods and compositions related to clot-binding lipid compounds |
| 04/07/2011 | DE102008005097B4 Antitumoraler Cyclodepsipeptide, deren Herstellung und Verwendung Antitumoral cyclodepsipeptides, their preparation and use |
| 04/07/2011 | CA2779506A1 Methods of improving vaccine immunogenicity |
| 04/07/2011 | CA2776779A1 Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| 04/07/2011 | CA2776464A1 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses |
| 04/07/2011 | CA2776462A1 (20s,22e)-2-methylene-19-nor-22-ene-1.alpha.,25-dihydroxyvitamin d3 analogs |
| 04/07/2011 | CA2776446A1 Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer |
| 04/07/2011 | CA2776327A1 Treatment of disease with proteasome inhibitors |
| 04/07/2011 | CA2776022A1 Antibodies that specifically bind to the epha2 receptor |
| 04/07/2011 | CA2775942A1 Pi3k (delta) selective inhibitors |
| 04/07/2011 | CA2775761A1 Combination immunotherapy for the treatment of cancer |
| 04/07/2011 | CA2775422A1 Bispecific binding molecules for anti-angiogenesis therapy |
| 04/07/2011 | CA2775420A1 Dll4-binding molecules |
| 04/07/2011 | CA2775418A1 Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
| 04/07/2011 | CA2774916A1 New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| 04/06/2011 | EP2305836A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
| 04/06/2011 | EP2305830A2 Method for evaluation of compound using RSK1 |
| 04/06/2011 | EP2305827A1 Cancer antigen MAGE-A9 and uses thereof |
| 04/06/2011 | EP2305796A1 Process for producing cytotoxic lymphocytes |
| 04/06/2011 | EP2305793A1 Process for producing cytotoxic lymphocytes |
| 04/06/2011 | EP2305716A2 Antibodies directed to gpnmb and uses thereof |
| 04/06/2011 | EP2305715A2 Monoclonal antibody to osteoprotegerin binding protein |
| 04/06/2011 | EP2305713A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305712A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305710A2 Synthetic antibody phage libraries |
| 04/06/2011 | EP2305700A1 Therapeutic USPA1-derived peptides |
| 04/06/2011 | EP2305699A1 Stabilised mRNA with increased G/C content which is optimised for translation in its coded areas |
| 04/06/2011 | EP2305694A2 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| 04/06/2011 | EP2305689A1 The synthesis of naturally occuring ecteinascidins and related compounds |
| 04/06/2011 | EP2305688A1 Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors |
| 04/06/2011 | EP2305687A1 Quinazoline derivatives |
| 04/06/2011 | EP2305682A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 04/06/2011 | EP2305679A1 Pyrazoline dione derivatives as nadph oxidase inhibitors |
| 04/06/2011 | EP2305677A1 Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor |
| 04/06/2011 | EP2305673A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 04/06/2011 | EP2305671A1 Thiophene and thiazole derivatives as CHK1 inhibitors |
| 04/06/2011 | EP2305642A2 Bis(thio-hydrazide amide) salts for treatment of cancers |
| 04/06/2011 | EP2305314A2 Remodelling and glycoconjugation of antibodies |
| 04/06/2011 | EP2305313A2 Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| 04/06/2011 | EP2305312A2 Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| 04/06/2011 | EP2305311A2 Glycoconjugation of peptides |
| 04/06/2011 | EP2305306A1 Neuroinvasion inhibitor |
| 04/06/2011 | EP2305304A1 Immunopotentiating agent comprising ep1 agonist |
| 04/06/2011 | EP2305300A1 Pharmaceutical composition for treatment and prevention of cancer |
| 04/06/2011 | EP2305291A1 Use of proteasome inhibitors for the treatment of HIV infections |
| 04/06/2011 | EP2305265A1 Combinations comprising staurosporines |
| 04/06/2011 | EP2305264A1 Spicamycin derivatives for use in decreasing or preventing pain |
| 04/06/2011 | EP2305263A1 Stabilized amorphous forms of imatinib mesylate |
| 04/06/2011 | EP2305257A1 Amonafide salts and compositions comprising same |
| 04/06/2011 | EP2305256A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 04/06/2011 | EP2305255A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 04/06/2011 | EP2305251A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder |
| 04/06/2011 | EP2305250A1 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 04/06/2011 | EP2305248A1 Substituted phenethylsulfones and method of reducing tnf-alpha levels |
| 04/06/2011 | EP2305243A1 Use of artemisinin and related compounds for treating diseases induced by human papilloma virus |
| 04/06/2011 | EP2305234A1 Pharmaceutical composition for treatment or prevention of hbv infection |
| 04/06/2011 | EP2305221A1 Dna damage repair inhibitors for treatment of cancer |
| 04/06/2011 | EP2305214A1 Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, and molecular imaging system and drug delivery system |
| 04/06/2011 | EP2304053A1 Identification and use of prognostic and predictive markers in cancer treatment |
| 04/06/2011 | EP2303924A2 Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same |
| 04/06/2011 | EP2303913A2 Crkl targeting peptides |
| 04/06/2011 | EP2303912A1 Cdca1 epitope peptides and vaccines containing the same |
| 04/06/2011 | EP2303910A1 Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents |
| 04/06/2011 | EP2303909A1 Iqgap3 epitope peptides and vaccines containing the same |
| 04/06/2011 | EP2303895A1 Thiazolyl- and oxazolyl-isoquinolinones and methods for using them |
| 04/06/2011 | EP2303891A1 Pyrazolo-quinazolines |
| 04/06/2011 | EP2303890A2 Phosphatidylinositol 3 kinase inhibitors |
| 04/06/2011 | EP2303887A1 Alpha helix mimetics and methods relating thereto |
| 04/06/2011 | EP2303885A1 Process for producing bicycloaniline derivatives |
| 04/06/2011 | EP2303882A2 Azacarboline derivatives, preparation method thereof and therapeutic use of same |
| 04/06/2011 | EP2303881A2 Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| 04/06/2011 | EP2303880A2 Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 04/06/2011 | EP2303875A2 Compositions with and process for methylmorpholin-subsituted pyrido[2,3-d]pyrimidines |
| 04/06/2011 | EP2303861A1 Pyridine compounds |
| 04/06/2011 | EP2303852A2 Inhibitors of akt activity |
| 04/06/2011 | EP2303823A1 Novel cinnamaldehyde derivatives having improved solubility in water, a method for preparing the same, a pharmaceutical composition comprising the same and a treatment method of cancer using the same |
| 04/06/2011 | EP2303407A1 Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells |